Figure 6.

SJ1-4 T cells control growth of fusion-expressing tumors in vivo and drive fusion-negative recurrences

(A) Schematic for in vivo experiments. Created using BioRender.

(B) IVIS images of tumor burden in mice treated with SJ1-4 T cells, mock-transduced T cells, or PBS.

(C) Tumor radiance measured by in vivo bioluminescence imaging for the first 21 days of study; n = 5 animals/group. A dashed line represents background bioluminescence (approximately 10⁶ photons/second). A red arrow indicates the day of T cell administration. 2-way ANOVA on log-transformed radiance values; ∗∗∗ p_adj < 0.001, ∗∗∗∗ p_adj < 0.0001.

(D) Survival curves for the duration of the study, n = 5 animals/group. Log rank test; ∗p < 0.05, ∗∗p < 0.01.

(E) Representative immunofluorescence of tumors harvested at euthanasia from mice treated with mock-transduced or SJ1-4 T cells. Blue, DAPI; green, GFP (tumor cells); red, tagBFP (cells expressing DNAJB1-PRKACA fusion); yellow, mCherry (transduced T cells).

(F) Quantification of GFP median fluorescence intensity (MFI) (left), tagBFP MFI (center), and number of mCherry⁺ T cells per μm² × 10⁴ (right). Wilcoxon rank-sum test; ∗ p_adj < 0.05, ∗∗ p_adj < 0.01, ∗∗∗ p_adj < 0.001, ∗∗∗∗ p_adj < 0.0001.

(G) Frequency of mCherry⁺ CD8 T cells in kidneys, livers, lungs, and spleens harvested at euthanasia from mice treated with mock-transduced or SJ1-4 T cells. Wilcoxon rank-sum test; ns, p > 0.05. See also Figures S7B–S7I.